Traders assign "No" a 95.5% implied probability for a new WHO-designated COVID variant of concern before 2027 because SARS-CoV-2 evolution has remained within Omicron sublineages without meeting VOC criteria since 2023. Ongoing genomic surveillance through mid-2026 shows dominant strains such as NB.1.8.1, XFG, and BA.3.2 classified only as variants under monitoring, with assessments indicating no substantial increases in transmissibility, severity, or immune escape that would trigger a higher designation. Reduced global sequencing volumes and stable low hospitalization rates further support this consensus, reflecting the shift to endemic management. A realistic shift could still occur if a highly divergent lineage suddenly drives measurable rises in severe outcomes or evades immunity enough to prompt WHO reclassification before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertJa
$244,719 Vol.
$244,719 Vol.
Ja
$244,719 Vol.
$244,719 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Markt eröffnet: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Traders assign "No" a 95.5% implied probability for a new WHO-designated COVID variant of concern before 2027 because SARS-CoV-2 evolution has remained within Omicron sublineages without meeting VOC criteria since 2023. Ongoing genomic surveillance through mid-2026 shows dominant strains such as NB.1.8.1, XFG, and BA.3.2 classified only as variants under monitoring, with assessments indicating no substantial increases in transmissibility, severity, or immune escape that would trigger a higher designation. Reduced global sequencing volumes and stable low hospitalization rates further support this consensus, reflecting the shift to endemic management. A realistic shift could still occur if a highly divergent lineage suddenly drives measurable rises in severe outcomes or evades immunity enough to prompt WHO reclassification before year-end.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert


Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen